Stephane Soulard

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Cost-Effectiveness of Earlier Diagnosis of Fibrotic Interstitial Lung Diseases (Fibrotic ILDs) and Earlier Treatment of Its Progressive Form, Progressive Pulmonary Fibrosis (PPF).

Cost-Effectiveness of Earlier Diagnosis of Fibrotic Interstitial Lung Diseases (Fibrotic ILDs) and Earlier Treatment of Its Progressive Form, Progressive Pulmonary Fibrosis (PPF).

Journal: Advances in therapy
Published: January 18, 2026

Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease.

Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease.

Journal: Advances in therapy
Published: August 31, 2023

I-PreFer Study: A Discrete Choice Experiment to Explore Patient, Caregiver and Pulmonologist Preferences of Idiopathic Pulmonary Fibrosis Pharmacological Treatment Options.

I-PreFer Study: A Discrete Choice Experiment to Explore Patient, Caregiver and Pulmonologist Preferences of Idiopathic Pulmonary Fibrosis Pharmacological Treatment Options.

Journal: Patient preference and adherence
Published: February 23, 2023

I-PreFer Study: A Questionnaire to Explore Patient, Caregiver and Pulmonologist Preferences of Idiopathic Pulmonary Fibrosis Treatment Options.

I-PreFer Study: A Questionnaire to Explore Patient, Caregiver and Pulmonologist Preferences of Idiopathic Pulmonary Fibrosis Treatment Options.

Journal: Patient preference and adherence
Published: February 23, 2023

Reducing carbon footprint by switching to reusable soft-mist inhalers.

Reducing carbon footprint by switching to reusable soft-mist inhalers.

Journal: ERJ open research
Published: October 14, 2022

Investigating the rationale for COPD maintenance therapy prescription across Europe, findings from a multi-country study.

Investigating the rationale for COPD maintenance therapy prescription across Europe, findings from a multi-country study.

Journal: NPJ primary care respiratory medicine
Published: May 13, 2022

Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries.

Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries.

Journal: ERJ open research
Published: October 22, 2021

Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study.

Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study.

Journal: BMJ open
Published: August 05, 2021

Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study.

Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study.

Journal: Advances in therapy
Published: September 09, 2020

The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease.

The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease.

Journal: Therapeutic advances in respiratory disease
Published: June 11, 2020

The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach.

The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach.

Journal: Advances in therapy
Published: March 15, 2020

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium.

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium.

Journal: PharmacoEconomics - open
Published: January 16, 2020
Showing 1-12 of 16

Last Updated: 09/26/2026